John Murphy is recorded as CFO at Progressive Corp (PGR), Analyst at Bank of America, Analyst at Bank of America Merrill Lynch, CFO at Coca Cola Co (KO) and Board Member at Cadrenal Therapeutics, Inc. (CVKD) since January 1, 2023. The newest filing on record that lists John Murphy as Board Member at Cadrenal Therapeutics, Inc. (CVKD) is dated August 3, 2026. Coca Cola Co reported in an 8-K filed June 25, 2026 that John Murphy was appointed President and Chief Financial Officer, effective August 1, 2026. Cadrenal Therapeutics, Inc. reported in an 8-K filed July 31, 2024 that John Murphy was appointed Class II director, effective July 29, 2024. Cadrenal Therapeutics, Inc. reported in an 8-K filed January 25, 2023 that John Murphy was appointed Class II director, effective January 19, 2023. Equibles holds 4 filed executive changes naming John Murphy; each is listed under recent activity with its source filing. The proxy statement of Progressive Corp reports total compensation of $3,462,301 for John Murphy in fiscal 2025, including a base salary of $627,115. Disclosed compensation is on record for 8 fiscal years. John Murphy has spoken on 42 earnings calls across 7 companies, most recently for Coca Cola Co on October 27, 2026. Those appearances were for Coca Cola Co (KO), Dauch Corp (DCH), OPENLANE, Inc. (OPLN), Penske Automotive Group, Inc. (PAG), Autonation, Inc. (AN) and 2 other companies. Coca Cola Co is classified in the Beverages - Non-Alcoholic industry within the Consumer Defensive sector. Cadrenal Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls John Murphy spoke on are classified in the Consumer Cyclical sector. Other leadership on record at Coca Cola Co includes Henrique Braun (CEO), James Quincey (Chairman and Board Member), Brian J. Smith (COO) and 7 others.
“Effective August 1, 2026, John Murphy, President and Chief Financial Officer, will assume responsibility for the North America Operating Unit on an interim basis.”
Coca Cola Co Form 8-K, filed June 25, 2026
· Read the filing
“The following two (2) individuals were elected as Class II directors, to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified with the following votes:”
Cadrenal Therapeutics, Inc. Form 8-K, filed July 31, 2024
· Read the filing
John Murphy on recent calls
“Our results once again demonstrate the strength and adaptability of our business. For the quarter, organic revenue grew 7%. Our unit cases grew 5%. Our two-year year-to-date volume growth average of 2% reflects a more sustained and balanced contribution to top-line revenue growth.”
“Our second quarter and first half results demonstrate the strength and consistency of our business model. Given the uneven external environment, we continue to use the many levers available to us to drive long-term growth.”
“First, I'd like to recognize James and congratulate him for his tremendous career and amazing leadership as our CEO. It's been an absolute honor working alongside you.”
“Today, I'll comment on our third quarter performance, discuss the outlook for the remainder of 2025, and provide some early commentary on 2026. During the third quarter, we grew organic revenues 6%.”
